» Articles » PMID: 17287410

Pathohistological Classification of Pituitary Tumors: 10 Years of Experience with the German Pituitary Tumor Registry

Overview
Specialty Endocrinology
Date 2007 Feb 9
PMID 17287410
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

In 1996, the German Registry of Pituitary Tumors was founded by the Pituitary Section of the German Society of Endocrinology as a reference center for collection and consultant pathohistological studies of pituitary tumors. The experiences of the first 10 years of this registry based on 4122 cases will herein be reported. The data supplement former collections of the years 1970-1995 with 3480 surgically removed tumors or lesions of the pituitary region. The cases were studied using histology, immunostainings and in some cases also molecular pathology or electron microscopy. The adenomas were classified according to the current World Health Organization classification in the version of 2004. From 1996 on 3489 adenomas (84.6%), 5 pituitary carcinomas (0.12%), 133 craniopharyngiomas (3.2%), 39 meningiomas (0.94%), 25 metastases (0.6%), 22 chordomas (0.5%), 115 cystic non-neoplastic lesions (2.8%), and 46 inflammatory lesions (1.1%, 248 other lesions or normal tissue (6.0%)) were collected by us. The adenomas (100%) were classified into densely granulated GH cell adenomas (9.2%), sparsely granulated GH cell adenomas (6.3%), sparsely granulated prolactin (PRL) cell adenomas (8.9%), densely granulated PRL cell adenomas (0.3%), mixed GH/PRL cell adenomas (5.2%), mammosomatotropic adenomas (1.1%), acidophilic stem cell adenomas (0.2%), densely granulated ACTH cell adenomas (7.2%), sparsely granulated ACTH cell adenomas (7.9%), Crooke cell adenomas (0.03%), TSH cell adenomas (1.5%), FSH/LH cell adenomas (24.8%), null cell adenomas (19.3%), null cell adenoma, oncocytic variant (5.8%), and plurihormonal adenomas (1.3%). Following the WHO classification of 2004, the new entity 'atypical adenoma' was found in 12 cases in 2005. Various prognostic parameters and clinical implications are discussed.

Citing Articles

Pituitary adenomas: biology, nomenclature and clinical classification.

Ho K, Melmed S Rev Endocr Metab Disord. 2025; .

PMID: 39862335 DOI: 10.1007/s11154-025-09944-x.


Spontaneous regression of paediatric pituitary lesions-report of 2 cases and literature review.

Esguerra J, Chan D, Tang P, Lek N, Low S Childs Nerv Syst. 2024; 41(1):6.

PMID: 39601895 DOI: 10.1007/s00381-024-06680-6.


Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.

Jotanovic J, Boldt H, Burton M, Andersen M, Bengtsson D, Bontell T Acta Neuropathol. 2024; 148(1):68.

PMID: 39580368 PMC: 11585505. DOI: 10.1007/s00401-024-02836-5.


Clinical features of pituitary carcinoma: analysis based on a case report and literature review.

Yang Y, Liang W, Fan K, Yang T, Cheng J Front Endocrinol (Lausanne). 2024; 15:1440247.

PMID: 39544231 PMC: 11560426. DOI: 10.3389/fendo.2024.1440247.


Growth dynamics of Rathke's Cleft cyst: a risk score system for surgical decision making.

Alsavaf M, Gosal J, Wu K, Varthya S, Abouammo M, Prevedello L Acta Neurochir (Wien). 2024; 166(1):407.

PMID: 39402369 PMC: 11473570. DOI: 10.1007/s00701-024-06299-1.